Effect of everolimus on skin cancers in calcineurin inhihitor-treated heart transplant recipients

Transplant International

Volumn 23, Issue 8, 2010, Pages 855-857

  Euvrard, Sylvie ^a   Boissonnat, Pascale ^b   Roussoulières, Ana ^b   Kanitakis, Jean ^a   Decullier, Evelyne ^c,d   Claudy, Alain ^a   Sebbag, Laurent ^b,e  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b LOUIS PRADEL HOSPITAL   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d UNIVERSITÉ DE LYON   (France)

^e UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ACTINIC KERATOSIS; AGED; BASAL CELL CARCINOMA; BLADDER CANCER; BOWEN DISEASE; CARDIAC GRAFT REJECTION; DIARRHEA; DRUG EFFECT; DRUG INDUCED CANCER; DRUG WITHDRAWAL; EDEMA; FOLLICULITIS; FOOT AND MOUTH DISEASE; GRAFT RECIPIENT; HEART GRAFT; HUMAN; HYPERLIPIDEMIA; ILEITIS; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEINURIA; PYREXIA IDIOPATHICA; SEBORRHEIC DERMATITIS; SKIN CANCER; SQUAMOUS CELL CARCINOMA; SUPPURATIVE HIDRADENITIS; ADULT; ANALOGS AND DERIVATIVES; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNOLOGY; MIDDLE AGED; SKIN NEOPLASMS;

ADULT; AGED; CALCINEURIN INHIBITORS; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SIROLIMUS; SKIN NEOPLASMS;

EID: 77954509263     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2009.01010.x     Document Type: Letter

References (15)

1. Crespo-Leiro MG, Alonso-Pulpón L, Vázquez de Prada JA, et al. Malignancy after heart transplantation: incidence, prognosis and risk factors. Am J Transplant 2008 8 : 1031.
2. Ulrich C, Kanitakis J, Stockfleth E, Euvrard S. Skin cancer in organ transplant recipients - where do we stand today? Am J Transplant 2008 8 : 2192. (Pubitemid 351229571)
3. Euvrard S, Kanitakis J, Decullier E, et al. Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 2006 81 : 1093. (Pubitemid 43754657)
4. Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immuno-suppressive agents used in organ transplantation. Transplantation 2004 77 : 1777. (Pubitemid 38822196)
5. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004 18 : 446. (Pubitemid 39077081)
6. Kauffman HM, Cherikh WS, Cheng U, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005 80 : 883.
7. Tessmer CS, Magalhaes LV, Keitel E, et al. Conversion to sirolimus in renal transplant recipients with skin cancer. Transplantation 2006 82 : 1792. (Pubitemid 46035669)
8. De Fijter JW. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation. Nephrol Dial Transplant 2007 22 (Suppl. 1 i23.
9. Campistol JM, Schena FP. Kaposi's sarcoma in renal transplant recipients - the impact of proliferation signal inhibitors. Nephrol Dial Transplant 2007 22 (Suppl. 1 i17.
10. Fernandez A, Marcen R, Pascual J, et al. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia. Transplant Proc 2006 38 : 2453. (Pubitemid 44693675)
11. Lévy A, Albiges Sauvin L, Massard C, Soria JC. Everolimus (RAD001) and solid tumours: a 2008 summary. Bull Cancer 2008 95 : 1205.
12. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005 11 : 1710. (Pubitemid 41641841)
13. Otley CC, Maragh SL. Reduction of immunosuppression for transplant associated skin cancer: rationale and evidence of efficacy. Dermatol Surg 2005 31 : 163.
14. Zuckermann A, Manito N, Epailly E, et al. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 2008 27 : 141. (Pubitemid 351221042)
15. Rival-Tringali AL, Euvrard S, Decullier E, Claudy A, Faure M, Kanitakis J. Conversion from calcineurin inhibitors to Sirolimus reduces vascularization and thickness of post-transplant cutaneous squamous cell carcinoma. Anticancer Res 2009 29 : 1927.